Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer

Cancer Research

Volumn 64, Issue 22, 2004, Pages 8405-8410

  Modrak, David E ^a,c   Cardillo, Thomas M ^a,b   Newsome, Guy A ^a   Goldenberg, David M ^a   Gold, David V ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b IMMUNOMEDICS INC   (United States)

^c GARDEN STATE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; GEMCITABINE; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL LOSS; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIPID METABOLISM; MITOCHONDRIAL MEMBRANE; PANCREAS CANCER; PRIORITY JOURNAL;

APOPTOSIS; CELL LINE, TUMOR; CERAMIDES; DEOXYCYTIDINE; DRUG SYNERGISM; ENZYME ACTIVATION; GLUCOSYLTRANSFERASES; HUMANS; PANCREATIC NEOPLASMS; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELINS;

EID: 8544264614     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2988     Document Type: Article

References (46)

1. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003;22:7414-30.
2. Birbes H, Bawab SE, Obeid LM, Hannun YA. Mitochondria and ceramide: intertwined roles in regulation of apoptosis. Adv Enzyme Regul 2002;42:113-29.
3. Pettus BJ, Chalfant CE, Hannun YA. Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta 2002;1585:114-25.
4. Hannun YA, Obeid LM. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 2002;277:25847-50.
5. Ogretmen B, Hannun YA. Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resist Updat 2001;4:368-77.
6. Sawai H, Hannun YA. Ceramide and sphingomyelinases in the regulation of stress responses. Chem Phys Lipids 1999;102:141-7.
7. Ruvolo PP. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 2003;47:383-92.
8. Radin NS. Killing cancer cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come? Eur J Biochem 2001;268:193-204.
9. Bleicher RJ, Cabot MC. Glucosylceramide synthase and apoptosis. Biochim Biophys Acta 2002;1585:172-8.
10. Santana P, Pena LA, Haimovitz-Friedman A, et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996;86:189-99.
11. Andrieu-Abadie N, Levade T. Sphingomyelin hydrolysis during apoptosis. Biochim Biophys Acta 2002;1585:126-34.
12. Sawai H, Domae N, Nagan N, Hannun YA. Function of the cloned putative neutral sphingomyelinase as lyso-platelet activating factor-phospholipase C. J Biol Chem 1999;274:38131-9.
13. Liu P, Anderson RG. Compartmentalized production of ceramide at the cell surface. J Biol Chem 1995;270:27179-85.
14. Fensome AC, Rodrigues-Lima F, Josephs M, Paterson HF, Katan M. A neutral magnesium-dependent sphingomyelinase isoform associated with intracellular membranes and reversibly inhibited by reactive oxygen species. J Biol Chem 2000;275:1128-36.
15. Tomiuk S, Zumbansen M, Stoffel W. Characterization and subcellular localization of murine and human magnesium-dependent neutral sphingomyelinase. J Biol Chem 2000;275:5710-7.
16. Chatterjee S, Han H, Rollins S, Cleveland T. Molecular cloning, characterization, and expression of a novel human neutral sphingomyelinase. J Biol Chem 1999;274:37407-12.
17. Hofmann K, Tomiuk S, Wolff G, Stoffel W. Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. Proc Natl Acad Sci USA 2000;97:5895-900.
18. Modrak DE, Rodriguez MD, Goldenberg DM, Lew W, Blumenthal RD. Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts. Int J Oncol 2002;20:379-84.
19. Modrak DE, Lew W, Goldenberg DM, Blumenthal R. Sphingomyelin potentiates chemotherapy of human cancer xenografts. Biochem Biophys Res Commun 2000;268:603-6.
20. Modrak DE, Cardillo TM, Gold DV, Goldenberg DM. Sphingomyelin enhances ceramide production and chemosensitivity of human gastrointestinal tumor xenografts. In: 94th Annual Meeting of the American Association for Cancer Research; 2003 July 11-14; Washington, DC. Philadelphia, PA: American Association for Cancer Research; 2003. p. LB-136.
21. Haller DG. New perspectives in the management of pancreas cancer. Semin Oncol 2003;30:3-10.
22. Modrak DE. Measurement of ceramide and sphingolipid metabolism in tumors: potential modulation of chemotherapy. In: Blumenthal RD, editor, Methods in molecular medicine. Totowa, NJ: Humana, 2005.
23. Liu B, Hannun YA. Sphingomyelinase assay using radiolabeled substrate. Methods Enzymol 2000;311:164-7.
24. Shayman JA, Abe A. Glucosylceramide synthase: assay and properties. Methods Enzymol 2000;311:42-9.
25. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Med Sci 1959;37:911-7.
26. Ames BN. Assay of inorganic phosphate, total phosphate and phosphatases. Methods Enzymol 1966;8:115-8.
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
28. Reynolds CP, Maurer BJ. Evaluating response to anti-neoplastic drug combinations in tissue culture models. In: Blumenthal RD, editor, Methods in molecular medicine. Totowa, NJ: Humana, 2005.
29. Liu YY, Han TY, Giuliano AE, Cabot MC. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 1999;274:1140-6.
30. Liu YY, Han TY, Giuliano AE, Hansen N, Cabot MC. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J Biol Chem 2000;275:7138-43.
31. Kruh GD. Introduction to resistance to anticancer agents. Oncogene 2003;22:7262-4.
32. Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003;22:7512-23.
33. Shabbits JA, Hu Y, Mayer LD. Tumor chemosensitization strategies based on apoptosis manipulations. Mol Cancer Ther 2003;2:805-13.
34. Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism-a strategy for overcoming drug resistance. J Natl Cancer Inst (Bethesda) 2001;93:347-57.
35. Menaldino DS, Bushnev A, Sun A, et al. Sphingoid bases and de novo ceramide synthesis: enzymes involved, pharmacology and mechanisms of action. Pharmacol Res 2003;47:373-81.
36. Maceyka M, Payne SG, Milstien S, Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta 2002;1585:193-201.
37. van Meer G, Lisman Q. Sphingolipid transport: rafts and translocators. J Biol Chem 2002;277:25855-8.
38. Miro Obradors MJ, Sillence D, Howitt S, Allan D. The subcellular sites of sphingomyelin synthesis in BHK cells. Biochim Biophys Acta 1997;1359:1-12.
39. Allan D, Quinn P. Resynthesis of sphingomyelin from plasma-membrane phosphatidylcholine in BHK cells treated with Staphylococcus aureus sphingomyelinase. Biochem J 1988;254:765-71.
40. Zhang P, Liu B, Jenkins GM, Hannun YA, Obeid LM. Expression of neutral sphingomyelinase identifies a distinct pool of sphingomyelin involved in apoptosis. J Biol Chem 1997;272:9609-12.
41. Veldman RJ, Maestre N, Aduib OM, Medin JA, Salvayre R, Levade T. A neutral sphingomyelinase resides in sphingolipid-enriched microdomains and is inhibited by the caveolin-scaffolding domain: potential implications in tumour necrosis factor signaling. Biochem J 2001;355:859-68.
42. Birbes H, El Bawab S, Hannun YA, Obeid LM. Selective hydrolysis of a mitochondrial pool of sphingomyelin induces apoptosis. FASEB J 2001;15:2669-79.
43. Decaudin D, Marzo I, Brenner C, Kroemer G. Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy (review). Int J Oncol 1998; 12:141-52.
44. Liu B, Obeid LM, Hannun YA. Sphingomyelinases in cell regulation. Semin Cell Dev Biol 1997;8:311-22.
45. Kok JW, Sietsma H. Sphingolipid metabolism enzymes as targets for anticancer therapy. Curr Drug Targets 2004;5:375-82.
46. Blumenthal RD, Modrak DE, Leon E, Gold DV, Goldenberg DM. Effect of sphingomyelin on the in vitro cytotoxic effects of radioimmunotherapy and naked antibody therapy. In: 95th Annual Meeting of the American Association for Cancer Research; 2004 March 27-31; Orlando, FL. Philadelphia, PA: American Association for Cancer Research; 2004. p. 957-8.